{
  "docId": "019de073-948a-7043-8b3b-a5ac9bb504f9",
  "docSlug": "d72f38beef66cb68e946399178678a94",
  "documentTitle": "Roivant Sciences | Investor Presentation Deck | 21 slides",
  "authorId": "roivant-sciences",
  "authorName": "Immunovant",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 21,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a grid layout to categorize medical indications by therapeutic area (Neurology, Hematology, Endocrinology, Rheumatology, Renal, Dermatology).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-948a-7043-8b3b-a5ac9bb504f9/5",
  "deckHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9",
  "deckJsonHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9.json",
  "deckAnchorHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.25,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "1. Indications announced or in development with anti-FcRn assets by Immunovant, Argenx, JNJ, and UCB. 2. If approved by regulatory authorities.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3e8e8b0-68eb-4cea-af4d-696c66b0cbe4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc0ef317-840a-432a-9837-70018b37a375",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.8,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "list",
      "text": "Neurology, Hematology, Endocrinology, Rheumatology, Renal, Dermatology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34a1c3cc-0c3a-4e40-83d9-8fc3845c1af5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "FcRn inhibition has broad potential in autoimmune diseases: 19 announced indications1 across multiple therapeutic areas create clinical and commercial2 opportunity for a franchise approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "adae5818-9cff-41a4-af15-f9b01938b57b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "2c5ba879-1777-41b1-a704-623cd78a5d10",
      "evidence": "Categorization of indications by therapeutic area",
      "confidence": 0.6
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}